M Cazorla1, J M Arrang, J Prémont. 1. Laboratory of Neurobiology & Molecular Pharmacology, Centre de Psychiatrie et Neurosciences, UMR-894 INSERM/Université Paris Descartes, 2Ter rue d'Alésia, Paris, France. mc3195@columbia.edu
Abstract
BACKGROUND AND PURPOSE: By interacting with trkB receptors, brain-derived neurotrophic factor (BDNF) triggers various signalling pathways responsible for neurone survival, differentiation and modulation of synaptic transmission. Numerous reports have implicated BDNF and trkB in the pathogenesis of various central nervous system affections and in cancer, thus representing trkB as a promising therapeutic target. In this study, we used an antibody-based approach to search for trkB-selective functional reagents. EXPERIMENTAL APPROACH: Six commercially available polyclonal and monoclonal antibodies were tested on recombinant and native, human and rodent trkB receptors. Functional and pharmacological characterization was performed using a modified version of the KIRA-elisa method and radioligand binding studies. Western blot analyses and neurite outgrowth assays were carried out to determine the specificity and selectivity of antibody effects. The survival properties of one antibody were further assessed on cultured neurones in a serum-deprived paradigm. KEY RESULTS: The functional trkB-selective antibodies showed distinct pharmacological profiles, ranging from partial agonists to antagonists, acting on trkB receptors through allosteric modulations. The same diversity of effects was observed on the mitogen-activated protein kinase signalling pathway downstream of trkB and on the subsequent neurite outgrowth. One antibody with partial agonist activity demonstrated cell survival properties by activating the Akt pathway. Finally, these antibodies were functionally validated as true trkB-selective ligands because they failed activating trkA or trkC, and contrary to BDNF, none of them bind to p75(NTR). CONCLUSIONS AND IMPLICATIONS: These trkB-selective antibodies represent a novel class of pharmacological tools to explore the pathophysiological roles of trkB and its potential therapeutic relevance for the treatment of various disorders.
BACKGROUND AND PURPOSE: By interacting with trkB receptors, brain-derived neurotrophic factor (BDNF) triggers various signalling pathways responsible for neurone survival, differentiation and modulation of synaptic transmission. Numerous reports have implicated BDNF and trkB in the pathogenesis of various central nervous system affections and in cancer, thus representing trkB as a promising therapeutic target. In this study, we used an antibody-based approach to search for trkB-selective functional reagents. EXPERIMENTAL APPROACH: Six commercially available polyclonal and monoclonal antibodies were tested on recombinant and native, human and rodent trkB receptors. Functional and pharmacological characterization was performed using a modified version of the KIRA-elisa method and radioligand binding studies. Western blot analyses and neurite outgrowth assays were carried out to determine the specificity and selectivity of antibody effects. The survival properties of one antibody were further assessed on cultured neurones in a serum-deprived paradigm. KEY RESULTS: The functional trkB-selective antibodies showed distinct pharmacological profiles, ranging from partial agonists to antagonists, acting on trkB receptors through allosteric modulations. The same diversity of effects was observed on the mitogen-activated protein kinase signalling pathway downstream of trkB and on the subsequent neurite outgrowth. One antibody with partial agonist activity demonstrated cell survival properties by activating the Akt pathway. Finally, these antibodies were functionally validated as true trkB-selective ligands because they failed activating trkA or trkC, and contrary to BDNF, none of them bind to p75(NTR). CONCLUSIONS AND IMPLICATIONS: These trkB-selective antibodies represent a novel class of pharmacological tools to explore the pathophysiological roles of trkB and its potential therapeutic relevance for the treatment of various disorders.
Authors: A Cattaneo; S Capsoni; E Margotti; M Righi; E Kontsekova; P Pavlik; P Filipcik; M Novak Journal: J Neurosci Date: 1999-11-15 Impact factor: 6.167
Authors: Eric J Nestler; Michel Barrot; Ralph J DiLeone; Amelia J Eisch; Stephen J Gold; Lisa M Monteggia Journal: Neuron Date: 2002-03-28 Impact factor: 17.173
Authors: C Zuccato; A Ciammola; D Rigamonti; B R Leavitt; D Goffredo; L Conti; M E MacDonald; R M Friedlander; V Silani; M R Hayden; T Timmusk; S Sipione; E Cattaneo Journal: Science Date: 2001-06-14 Impact factor: 47.728
Authors: Rachael S Allen; Adam M Hanif; Marissa A Gogniat; Brian C Prall; Raza Haider; Moe H Aung; Megan C Prunty; Lukas M Mees; Monica M Coulter; Cara T Motz; Jeffrey H Boatright; Machelle T Pardue Journal: Eur J Neurosci Date: 2018-04-03 Impact factor: 3.386
Authors: Vinay Bhaskar; Ira D Goldfine; Daniel H Bedinger; Angela Lau; Hua F Kuan; Lisa M Gross; Masahisa Handa; Betty A Maddux; Susan R Watson; Shirley Zhu; Ajay J Narasimha; Raphael Levy; Lynn Webster; Sujeewa D Wijesuriya; Naichi Liu; Xiaorong Wu; David Chemla-Vogel; Catarina Tran; Steve R Lee; Steve Wong; Diane Wilcock; Mark L White; John A Corbin Journal: Diabetes Date: 2012-03-08 Impact factor: 9.461
Authors: Daniel Todd; Ian Gowers; Simon J Dowler; Michael D Wall; George McAllister; David F Fischer; Sipke Dijkstra; Silvina A Fratantoni; Rhea van de Bospoort; Jessica Veenman-Koepke; Geraldine Flynn; Jamshid Arjomand; Celia Dominguez; Ignacio Munoz-Sanjuan; John Wityak; Jonathan A Bard Journal: PLoS One Date: 2014-02-04 Impact factor: 3.240
Authors: John A Corbin; Vinay Bhaskar; Ira D Goldfine; Daniel H Bedinger; Angela Lau; Kristen Michelson; Lisa M Gross; Betty A Maddux; Hua F Kuan; Catarina Tran; Llewelyn Lao; Masahisa Handa; Susan R Watson; Ajay J Narasimha; Shirley Zhu; Raphael Levy; Lynn Webster; Sujeewa D Wijesuriya; Naichi Liu; Xiaorong Wu; David Chemla-Vogel; Steve R Lee; Steve Wong; Diane Wilcock; Mark L White Journal: PLoS One Date: 2014-02-12 Impact factor: 3.240